Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1664-1671

  Majlis, Alejandro ^a   Pugh, William C ^a   Rodriguez, Maria A ^a   Benedict, William F ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MEPREDNISONE; MESNA; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE LOCUS; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MANTLE CELL LYMPHOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING; TUMOR BIOPSY;

EID: 0030907171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1664     Document Type: Article

References (48)

1. Banks PM, Chan J, Cleary ML: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 16:637-640, 1992
2. Tolksdorf G, Stein H, Lennert K: Morphological and immuno-logical definition of a malignant lymphoma derived from germinal-center with cleaved nuclei (centrocytes). Br J Cancer 41:168-182, 1980
3. Berard CW: Reticuloendothelial system: An overview of neoplasia, in Rebuck JW, Berard C, Abell MR (eds): International Academy of Pathology Monograph, vol 16. Baltimore, MD, Williams & Wilkins, 1975, p 301-317
4. Engelhard M, Meusers P, Brittinger G, et al: Prospective multicenter trial for the response adapted treatment of high grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 2:177-180, 1991 (suppl 2)
5. Weisenburger DD, Kim H, Rappaport H: Mantle zone lymphoma: A follicular variant of intermediate lymphocyte lymphoma. Cancer 49:1429-1438, 1982
6. Namba K, Jaffe ES, Braylan RC, et al: Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. Am J Clin Pathol 68:535-542, 1977
7. Jaffe ES, Bookman MA, Longo DL: Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma: A distinct subtype of B-cell lymphoma. Hum Pathol 18:877-880, 1987
8. Withers DA, Harvey RC, Faust JB, et al: Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846-4853, 1991
9. Seto M, Yamamoto K, Iida S, et al: Gene rearrangement and overexpression of PRAD-1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 7:1401-1406, 1992
10. Williams ME, Meeker TC, Swerdlow SH: Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes. Blood 78:493-498, 1991
11. Williams ME, Swerdlow SH, Rosenberg CL, et al: Chromosome 11 translocation breakpoints at the PRAD 1 cyclin gene locus in centrocytic lymphoma. Leukemia 7:241-245, 1993
12. Williams ME, Swerdlow SH, Rosenberg CL, et al: Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD-1 in centrocytic lymphoma loci. Cancer Res 52:5541s-5544s, 1992 (suppl)
13. Rosenberg CL, Wong E, Petty EM, et al: PRAD 1, a candidate BCL-1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci 88:9638-9642, 1991
14. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
15. The Non-Hodgkin's Lymphoma Pathological Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
16. Weisenburger DD, Duggan MJ, Perry DA, et al: Non-Hodgkin's lymphomas of mantle zone origin. Pathol Annu 26:139-158, 1991
17. Weisenburger DD: Mantle cell lymphoma, in Knowles DM (ed): Neoplastic Hematopathology. Baltimore, MD, Williams & Wilkins, 1992, pp 617-628
18. Carbone A, Poletti A, Manconi R, et al: Intermediate lymphocytic lymphoma encompassing diffuse and mantle zone pattern variants: A distinct entity among low grade lymphoma? Eur J Cancer Clin Oncol 25:113-129, 1989
19. Perry DA, Bast MA, Armitage JO, et al: Diffuse intermediate lymphocytic lymphoma: A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 66:1995-2000, 1990
20. Lardelli P, Bookman MA, Sundeen J, et al: Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14:752-763, 1990
21. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa associated lymphoid tissue and monocytoid B cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
22. Carbone PP, Kaplan HS, Musshoff K, et al: Report on the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
23. Rodriguez J, Cabanillas F, McLaughlin P, et al: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann Oncol 3:711-717, 1992
24. Yang WI, Zukerberg LR, Motokura T, et al: Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 145:86-96, 1994
25. Osborne BM, Butler JJ, Pugh WC: The value of immunophenotyping on paraffin sections in the identification of T cell rich B large cell lymphomas. Am J Surg Pathol 14:933-938, 1990
26. McKelvey EM, Gottlieb JA, Wilson HE: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
27. Cabanillas F, Rodriguez MA, Swan F: Recent trends in the management of lymphomas at M.D. Anderson Cancer Center. Semin Oncol 17:28-32, 1990
28. Alexanian R, Dimopoulos M: Drug therapy: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994
29. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
30. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Berard CW, Dorfman RF: Histopathology of malignant lymphomas. Clin Haematol 3:39-76, 1974
32. Jaffe ES, Braylan RC, Nanba K, et al: Funtcional markers: A new perspective on malignant lymphomas. Cancer Treat Rep 61:953-962, 1977
33. Lennert K: Malignant Lymphomas Other Than Hodgkin's Disease. Berlin, Germany, Springer-Verlag, 1978
34. Palutke M, Eisenberg L, Mirchandani I, et al: Malignant lymphoma of small cleaved lymphocytes of the follicular mantle zone. Blood 59:317-322, 1982
35. Raffeld M, Jaffe ES: bcl-1, t(11:14), and mantle cell-derived lymphomas. Blood 78:259-263, 1991 (editorial)
36. Weisenburger DD, Linder J, Daley DT, et al: Intermediate lymphocytic lymphoma: An immunohistologic study with comparison to other lymphocytic lymphomas. Hum Pathol 18:781-790, 1987
37. Rodriguez M, Pugh W, Ince A, et al: Clinical and histologic characteristics of lymphomas with the translocation (11;14) (q13;q32). Proc Am Soc Clin Oncol 8:998a, 1989 (abstr)
38. Weisenburger DD, Sanger WG, Armitage JO, et al: Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic finding. Blood 69:1617-1621, 1987
39. Ince C, Blick M, Lee M, et al: Bel-1 gene rearrangements in B cell lymphoma. Leukemia 2:343-346, 1988
40. Tsujimoto Y, Jaffe ES, Cossman J, et al: Clustering of breakpoints on chromosome 11 in human B cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340-343, 1985
41. Leroux D, Le-MarcHadour F, Gressin R, et al: Non-Hodgkin's lymphomas with t(11;14)(q13;q32): A subset of mantle zone/intermediate lymphocytic lymphoma? Br J Haematol 77:346-353, 1991
42. Arnold A, Kim HG, Gaz RD, et al: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83:2034-2040, 1989
43. Paterlini P, Suberville AM, Zindy F, et al: Cyclin A expression in human hematological malignancies: A new marker of cell proliferation. Cancer Res 53:235-238, 1993
44. de Boer CJ, Loyson S, Kluin PM, et al: Multiple breakpoints within the bcl-1 locus in B cell lymphoma: Rearrangement of the cyclin D1 gene. Cancer Res 53:4148-4152, 1993
45. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 350:512-518, 1991
46. Duggan MJ, Weisenburger DD, Ye YL, et al: Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 66:522-529, 1990
47. Bookman MA, Lardelli P, Jaffe ES, et al: Lymphocytic lymphoma of intermediate differentiation: Morphologic, immunophenotypic, and prognostic factors. J Natl Cancer Inst 82:742-748, 1990
48. Isaacson P, Wright DH: Extranodal mucosa-associated lymphoid tissue. Cancer 53:2515-2524, 1984